Your session is about to expire
← Back to Search
Hydroxychloroquine + Encorafenib/Cetuximab for Colorectal Cancer
Study Summary
This trial studies adding hydroxychloroquine to cancer treatments to improve effectiveness in BRAF V600E colon cancer patients.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have cancer that has spread to my brain or spinal cord.I have a history of pancreatitis.I have another cancer that won't affect this treatment's safety or results.I am not pregnant or nursing.I haven't had chemotherapy or radiotherapy in the last 14 days.My organs and bone marrow are functioning well.I stopped my previous cancer treatments at least 14 days ago.I haven't taken strong CYP3A4/5 inhibitors or inducers in the last week.I can swallow pills and don't have major stomach or intestine issues.I am not pregnant and agree to use birth control.I am 18 years old or older.I have HIV but my viral load is undetectable with treatment.My brain cancer has not worsened after treatment.I have recovered from previous cancer treatments with minimal side effects.My heart condition does not severely limit my physical activity.I do not have any uncontrolled illnesses like heart problems or infections.I have conditions like psoriasis or porphyria.I am fully active or can carry out light work.My colorectal cancer is stage IV with a BRAF V600E mutation, and I've had at least one treatment but no BRAF inhibitors.I have chronic hepatitis B but it's under control with medication.I had hepatitis C but am now cured or currently being treated with an undetectable viral load.
- Group 1: Treatment (Hydroxychloroquine)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is it still possible to join this medical experiment?
"Clinicaltrials.gov states that this experiment is actively recruiting patients, with the initial post being made on October 10th 2022 and an alteration occurring on November 16th 2022."
How many participants is the research team accepting for this trial?
"Affirmative. According to clinicaltrials.gov, this medical experiment is presently recruiting participants and was first posted on October 10th 2022. The most recent edits were done on November 16th 2022 and the research team requires 43 volunteers at one location."
To what degree can Hydroxychloroquine be relied upon as a safe treatment option?
"Given the lack of clinical data confirming efficacy and some evidence for safety, Treatment (Hydroxychloroquine) was rated a 2 on our scale from 1 to 3."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger